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Abstract
Background
Idiopathic pulmonary fibrosis (IPF) is an independent risk factor for lung cancer (LC) devel-
opment; however, its effect on recurrence after curative surgery remains unclear.
Objectives
This study aimed to determine the impact of IPF on recurrence-free survival following cura-
tive surgical resection of stage I–III non-small cell lung cancer (NSCLC) and investigate the
effects of patient and surgical factors on the risk of recurrence.
Methods
We reviewed retrospectively collected data of patients with surgically resected stage I–III
NSCLC from two tertiary care hospitals in South Korea. By propensity score matching,
patients with IPF (LC with IPF) were matched to those without IPF (LC without IPF).
Results
In total, 3416 patients underwent surgical resection, and 96 were diagnosed with underlying
IPF. In the LC with IPF group, 89.6% patients were men, and the average age was 69.7
years. Sublobar resection was performed more frequently in the LC with IPF group than
in the LC without IPF group, while the rate of mediastinal lymph node dissection and dis-
sected node number were lower in the former group. The 5-year recurrence-free survival
rate was significantly lower in the LC with IPF group (49.2%) than in the LC without IPF
group (69.1%; P<0.001). Multivariable Cox regression analysis revealed that IPF and post-
operative stage III were independent risk factors for recurrence.
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Conclusions
IPF may increase the risk of recurrence after curative surgical treatment for NSCLC. Close
surveillance for recurrence is mandatory for patients with underlying IPF.
Introduction
Idiopathic pulmonary fibrosis (IPF) is a devastating lung disease characterized by progressive
lung scarring and a histopathological pattern of usual interstitial pneumonia (UIP). The
median survival period of IPF ranges from 2.5 to 3.5 years [1, 2]. Patients with IPF exhibit a
high prevalence of various comorbidities, including chronic obstructive lung disease, pulmo-
nary hypertension, coronary artery disease, and lung cancer (LC) [3].
The reported prevalence of LC in patients with IPF is 2.7%–45.7% [4–8]. Moreover, the rel-
ative risk of LC development is approximately eight times higher in patients with IPF than in
the general population [9]. Although adenocarcinoma is the most common histopathological
type of LC in the general population, patients with IPF are most commonly affected by squa-
mous cell carcinoma, followed by adenocarcinoma [8, 10, 11].
Patients with stage I and stage II non-small cell lung cancer (NSCLC), as well as those with
certain stage III NSCLCs, are considered eligible for curative resection. Complete resection,
when possible, remains the mainstay of therapy and is associated with the highest probability
of long-term survival. However, if patients with LC who were eligible for surgical resection
have underlying IPF, several aspects must be considered. Previous studies have shown that the
postoperative morbidity and mortality rates for patients with NSCLC are significantly higher if
IPF is present, with the main cause of postoperative mortality being acute exacerbation of IPF
(AE-IPF) [12–16]. A few studies have reported the long-term survival of patients with NSCLC
and IPF, although overall survival was significantly poorer for these patients than for those
without IPF [14, 17–20]. However, the effect of IPF on recurrence after curative surgical treat-
ment for NSCLC remains unclear. Therefore, the present study aimed to determine the impact
of IPF on recurrence-free survival and overall survival following curative surgical resection of




We retrospectively reviewed the medical records of patients with stage I–III NSCLC who
underwent curative resection at Seoul National University Bundang Hospital and Severance
Hospital between January 2003 and September 2016. Among these patients, we identified
those who were diagnosed with underlying IPF. By propensity score matching of confounding
variables, including age, sex, the histopathological subtype of NSCLC, the postoperative stage
of NSCLC, and the year of NSCLC diagnosis, patients with IPF (LC with IPF group) were
matched to those without IPF (LC without IPF group) in a 1:2 ratio. Flow chart of patient
recruitment is shown in Fig 1. This study was conducted in accordance with the amended
Declaration of Helsinki. Local institutional review boards and independent ethics committees
approved the study protocol (Seoul National University Bundang Hospital, IRB number: B-
1707/411-402; Severance Hospital, IRB number: 4-2019-0292).
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lungs for carbon monoxide; FVC, forced vital
capacity; HR, hazard ratio; IPF, idiopathic
pulmonary fibrosis; LC, lung cancer; NSCLC, non-
small cell lung cancer.
Ethics approval and consent to participate
This study was approved by the Institutional Review Board and Ethics Committee of Seoul
National University Bundang Hospital and Severance Hospital (Seoul National University
Bundang Hospital, IRB number: B-1707/411-402; Severance Hospital, IRB number: 4-2019-
0292). Written informed consent was waived as the nature of retrospective study by IRB. The
patient’s medical records between January 2003 and September 2016 were accessed. All data
were fully anonymized before accessement.
Definitions
In accordance with diagnostic criteria defined by the International Consensus Statement of
the American Thoracic Society and European Respiratory Society in 2018 [1], IPF was diag-
nosed via a multidisciplinary approach involving pulmonologists as well as radiologists and
pathologists specializing in chest diseases.
The LC stage was defined according to the 8th edition of the American Joint Committee on
Cancer staging system. Recurrence-free survival was defined as the time from surgery to the
first diagnosis of disease recurrence or the last follow-up visit. Death was considered a censoring
event for recurrence. Overall survival was defined as the time from initial LC treatment to death
or the last follow-up visit. Local recurrence was defined as evidence of tumor cells within the
same lobe of the lung or ipsilateral pulmonary hilum, and regional recurrence was defined as
evidence of tumor cells within another lobe of the ipsilateral lung or the ipsilateral or subcarinal
lymph nodes (LNs), while distant metastasis was defined as evidence of tumor cells in the con-
tralateral lung, contralateral mediastinal LNs, the pleural space, or areas outside the hemithorax.
AE-IPF was defined as acute, clinically significant respiratory deterioration characterized
by evidence of new widespread alveolar abnormality, in accordance with the diagnostic criteria
proposed by Collard et al. in 2016 [21].
Fig 1. Patient recruitment flow chart.
https://doi.org/10.1371/journal.pone.0235126.g001
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The gender–age–physiology (GAP) index was applied for the assessment of the severity and
prognosis of IPF. The index was calculated as follows: gender (0–1 point), age (0–2 points),
forced vital capacity (FVC; 0–2 points), and diffusing capacity of the lungs for carbon monox-
ide (DLCO; 0–3 points). Based on the score, IPF was categorized into three stages: I (0–3
points), II (4–5 points), and III (6–8 points). The predicted 1-year mortality rates for GAP
stages I, II, and III were 6%, 16%, and 39%, respectively [22].
Statistical analysis
Propensity scores were estimated through multiple logistic regression analysis with sex, age,
the postoperative cancer stage, the histopathological subtype of cancer, and the year of cancer
diagnosis as independent variables.
Using the matched set, we examined the effect of IPF on recurrence after curative surgical
resection of stage I–III NSCLC. Generalized estimating equations were used to compare con-
tinuous and categorical variables of propensity score matched population. Cumulative time-
to-event distributions (survival, recurrence) were estimated using the stratified Kaplan–Meier
method. Independent predictors for recurrence and overall survival were determined by strati-
fied Cox proportional hazards models. A P-value <0.05 was considered statistically significant.
All statistical analyses were performed using SAS software (version 9.4; SAS Inc., Cary, NC,
USA).
Results
Patient characteristics and surgical methods
In total, 3416 patients with NSCLC underwent surgical resection during the study period, and
96 were diagnosed with underlying IPF. Baseline characteristics of the overall cohort before
propensity score matching are shown in Table 1. The LC with IPF group and LC without IPF
group showed significant differences in potential confounding factors for recurrence, includ-
ing age, sex, the histopathological subtype, and the postoperative stage. The average age (69.7
years vs 63.4 years; P<0.001) and proportion of men (89.6% vs 61.8%; P<0.001) were higher
Table 1. Baseline characteristics of patients with surgically resected non-small cell lung cancer.
LC with IPF (n = 96) LC without IPF (n = 3316) P-value
Sex (male) 86 (89.6%) 2049 (61.8%) <0.001
Age (year) 69.7 ± 7.4 63.4 ± 10.0 <0.001
Histology <0.001
Adenocarcinoma 44 (45.8%) 2262 (68.2%)
Squamous cell carcinoma 48 (50.0%) 922 (27.8%)
Adenosquamous 2 (2.1%) 42 (1.3%)
Large cell 0 (0.0%) 64 (1.9%)
Sarcomatoid 2 (2.1%) 26 (0.8%)
Postoperative Stage <0.001
0 – 74 (2.2%)
I 43 (44.8%) 2123 (64.0%)
II 35 (36.5%) 608 (18.3%)
III 18 (18.8%) 511 (15.4%)
Values are expressed as the mean ± standard deviation or number (%).
IPF, idiopathic pulmonary fibrosis; LC, lung cancer
https://doi.org/10.1371/journal.pone.0235126.t001
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in the LC with IPF group than in the LC without IPF group. The most frequent histopatholog-
ical subtype was squamous cell carcinoma in the LC with IPF group and adenocarcinoma in
the LC without IPF group. Patients with IPF showed more advanced postoperative stages
(stages II and III) than did those without IPF.
Baseline characteristics of the matched groups are shown in Table 2. The diffusing capacity
of the lungs for carbon monoxide (DLCO) was significantly lower in the LC with IPF group
than in the LC without IPF group (83.7±20.8 vs. 104.3±24.7; P<0.001). Other variables, includ-
ing the location of the primary tumor, forced vital capacity (FVC), and forced expiratory vol-
ume in one second, were comparable between groups. In the LC with IPF group, stages I and
II as per the GAP index were documented for 94 (97.9%) and two (2.1%) patients, respectively.
There was no patient with GAP stage III.
The treatment-related characteristics of the matched groups are shown in Table 3. There
was no significant difference in the proportion of patients receiving induction therapy and
adjuvant therapy between the two groups. Sublobar resection, either wedge resection or seg-
mentectomy, was more frequently performed in the LC with IPF group than in the LC without
IPF group, while the rate of mediastinal lymph node dissection was lower in the LC with IPF
group (82.3% vs. 99.0%; P<0.001). The mean number of dissected LNs was also smaller in the
LC with IPF group than in the LC without IPF group (16.0 vs. 23.2; P<0.001). The two groups
showed no significant difference in the resection margin status (R0, complete resection; R1,
microscopic residual tumor).
Treatment-related complications
To assess the incidence of treatment-related complications, we defined the duration between
the last treatment and the onset of complications as�4 weeks (Table 4). The incidence of sur-
gery-related AE-IPF or acute respiratory distress syndrome (ARDS) was significantly higher in
the LC with IPF group than in the LC without IPF group. Adjuvant treatment-related compli-
cation rates were comparable between groups. Surgery and adjuvant treatment resulted in
AE-IPF in 5.2% and 6.7% patients, respectively.
Recurrence and mortality
During a median follow-up period of 49.2 months, 92 recurrences were documented for the
entire matched study population. Recurrences were significantly more frequent in the LC with
IPF group than in the LC without IPF group (44.8% vs. 25.5%; P = 0.002). Among the patients
with recurrence, the type of recurrence (local, regional recurrence or distant metastasis) did
not show significant difference between groups. The 5-year recurrence-free survival rate
(49.2%; 95% CI, 39.4–61.4 vs. 69.1%; 95% CI, 61.9–77.0; P<0.001; Fig 2, Table 5) and 5-year
overall survival rate (45.9%; 95% CI, 36.5–57.7 vs. 64.8%; 95% CI, 57.9–72.6; P<0.001; Fig 2,
Table 5) were significantly lower in the LC with IPF group than in the LC without IPF group.
Cancer-specific survival was also significantly lower in the LC with IPF group than in the LC
without IPF group (P = 0.008, S1A Fig, Table 5).
Predictors of recurrence
Univariable Cox proportional hazards regression analysis revealed that IPF, the postoperative
stage, surgical extent, and rate of mediastinal lymph node dissection were major predictors of
recurrence after surgical treatment. These variables and additional potential confounding vari-
able were combined in multivariable regression analysis, which revealed that IPF (HR, 2.68;
95% CI, 1.53–5.76; P = 0.001) and postoperative stage III (vs. stage I; HR, 5.46; 95% CI, 1.72–
17.37; P = 0.004) were independent predictors of recurrence (Table 6).
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Table 2. Baseline characteristics of patients with surgically resected non-small cell lung cancer with or without idiopathic pulmonary fibrosis (propensity score-
matched population).
LC with IPF (n = 96) LC without IPF (n = 192) P-value
Sex (male) 86 (89.6) 169 (88.02) 0.602
Age (year) 69.7 ± 7.4 69.0 ± 6.6 0.417
BMI (kg/m2) 24.0 ± 2.8 23.8 ± 3.9 0.503
Smoking exposure 0.642
Never 11 (11.5) 43 (22.4)
Former 71 (74.0) 107 (55.7)
Current 14 (14.6) 42 (21.9)
Smoking (pack-years) 37.1 ± 25.7 34.9 ± 32.1 0.501
Comorbidities
Hypertension 44 (45.8) 73 (38.0) 0.204
Diabetes mellitus 26 (27.1) 37 (19.3) 0.167
COPD 11 (11.5) 21 (10.9) 0.899
Old TB 18 (18.8) 28 (14.6) 0.346
Other cancer 17 (17.7) 31 (16.2) 0.726
Coronary artery disease 7 (7.3) 24 (12.5) 0.161
Cerebrovascular disease 3 (3.1) 10 (5.2) 0.436
Histology 0.157
Adenocarcinoma 44 (45.8) 92 (47.9)
Squamous cell carcinoma 48 (50.0) 96 (50.0)
Adenosquamous 2 (2.1) 1 (0.5)
Large cell 0 (0.0) 3 (1.6)
Sarcomatoid 2 (2.1) 0 (0.0)
Location 0.379
Right upper lobe 16 (16.7) 35 (18.2)
Right middle lobe 5 (5.2) 11 (5.7)
Right lower lobe 27 (28.1) 58 (30.2)
Left upper lobe 23 (24.0) 51 (26.6)
Left lower lobe 25 (26.0) 37 (19.3)
Pulmonary function test
FVC % pred 93.5 ± 13.2 94.7 ± 15.5 0.503
FEV1% pred 98.4 ± 15.4 96.6 ± 20.2 0.411
DLCO % pred
� 83.7 ± 20.8 104.3 ± 24.7 (n = 153) <0.001
Postoperative Stage 0.665
I 43 (44.8) 85 (44.3)
II 35 (36.5) 79 (41.2)
III 18 (18.8) 28 (14.6)
Severity of IPF (GAP stage)
I 94 (97.9) –
II 2 (2.1) –
Values are expressed as the mean ± standard deviation or number (%).
BMI, body mass index; COPD, chronic obstructive pulmonary disease; DLCO, diffusing capacity of the lungs for carbon monoxide; ECOG, Eastern Cooperative
Oncology Group; FEV1, forced expiratory volume in one second; FVC, forced vital capacity; GAP, gender, age, and physiology; IPF, idiopathic pulmonary fibrosis; LC,
lung cancer
�39 patients with missing data in LC without IPF group
https://doi.org/10.1371/journal.pone.0235126.t002
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Predictors of overall survival
Univariable Cox proportional hazards regression analysis revealed that IPF, Eastern Coopera-
tive Oncology Group score, FVC, postoperative stage, surgical extent, and surgery-related
AE-IPF or ARDS were major covariates for overall survival. These variables and additional
potential confounding variable were combined in multivariable analysis, which revealed that
IPF (HR, 1.98; 95% CI, 1.12–3.47; P = 0.018), postoperative stage III NSCLC (vs. stage I; HR,
3.39; 95% CI, 1.28–8.97; P = 0.014), and surgery-related AE-IPF or ARDS (HR, 14.02; 95% CI,
1.55–126.89; P = 0.019) were independent predictors of overall survival (Table 6).
Discussion
In the present study, we demonstrated the impact of IPF on recurrence and survival following
curative surgical resection of stage I–III NSCLC in a propensity score-matched study popula-
tion. Both recurrence-free survival and overall survival after curative surgical resection were
significantly compromised in patients with IPF. IPF and postoperative stage III were predic-
tors of both recurrence and overall survival. Surgery-related AE-IPF or ARDS was also identi-
fied as an independent risk factor for mortality.
Epidemiological studies have revealed that IPF is an independent risk factor for LC devel-
opment [4, 6, 11, 23], although the pathogenesis connecting the two diseases remains poorly
understood. Common pathways for the development of LC in IPF, yet with distinct roles in
the pathogenesis of both conditions, include genetic and epigenetic alterations; abnormal
Table 3. Treatment-related variables for patients with surgically resected non-small cell lung cancer with or without idiopathic pulmonary fibrosis (propensity
score-matched population).
LC with IPF (n = 96) LC without IPF (n = 192) P-value
Induction treatment 0.273
Chemotherapy 1 (1.0) 5 (2.6)
Concurrent chemoradiotherapy 0 (0.0) 1 (0.5)
Surgery
Surgical extent <0.001
Wedge resection 16 (16.7) 3 (1.6)
Segmentectomy 8 (8.3) 8 (4.2)
Lobectomy 70 (72.9) 150 (78.1)
Bilobectomy 1 (1.0) 18 (9.4)
Pneumonectomy 1 (1.0) 13 (6.8)
MLND 79 (82.3) 190 (99.0) <0.001
Dissected LN 16.0 ± 13.4 23.2 ± 12.8 <0.001
Number of positive LN 1.0 ± 2.3 1.1 ± 2.4 0.629
Resection margin 0.481
R0 92 (95.8) 180 (93.8)
R1 4 (4.2) 12 (6.3)
Adjuvant treatment 0.187
Chemotherapy 24 (25.0) 64 (33.3)
Radiotherapy 3 (3.1) 4 (2.1)
Concurrent chemoradiotherapy 0 (0.0) 7 (3.7)
Sequential radiotherapy after chemotherapy 3 (3.1) 5 (2.6)
Values are expressed as mean ± SD or number (%).
IPF, idiopathic pulmonary fibrosis; MLND, mediastinal lymph node resection; LC, lung cancer; LN, lymph node
https://doi.org/10.1371/journal.pone.0235126.t003
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expression of microRNAs; cellular and molecular aberrances; and activation of specific signal-
ing transduction pathways [24–26]. Several pieces of evidence related to therapeutic agents
also suggest a pathogenic link between IPF and LC. Nintedanib, which was first approved for
use in combination with docetaxel for the second-line treatment of advanced NSCLC [27], has
also been approved as an antifibrotic agent for the treatment of IPF. A previous retrospective
study reported that the incidence of LC was lower in patients with IPF receiving pirfenidone,
another antifibrotic agent approved for IPF treatment, than in those without pirfenidone treat-
ment [28], while a preclinical experiment showed that the combination of pirfenidone and cis-
platin led to increased apoptosis and synergistic death of both cancer-associated fibroblasts
and NSCLC cells [29].
Patients with LC and underlying IPF are commonly encountered in clinical practice; how-
ever, for these patients, it is difficult to predict the efficacy of treatment for LC due to the
increased incidence of treatment-related complications and poor prognosis of IPF itself [12–
14, 30]. Reports on the long-term prognosis of patients with NSCLC accompanied by IPF who
underwent curative surgical resection have consistently documented lower 5-year survival and
recurrence-free survival for patients with IPF than for those without [14, 17–20]. In a study
performed by the Japanese Association for Chest Surgery, which analyzed predictors of overall
survival after the surgical treatment of LC in patients with interstitial lung disease [31], it was
found that wedge resection, a predicted FVC of<80%, and tumors located in the inferior lobe
were poor prognostic factors for overall survival. Furthermore, subgroup analysis of patients
with stage I cancer showed that the survival curves for those treated with wedge resection and
those treated with lobectomy crossed at approximately 1 year after surgery, with 5-year sur-
vival rates of 29.2% and 68.6%, respectively. From this result, the authors inferred that wedge
Table 4. Treatment-related complications in patients with surgically resected non-small cell lung cancer with or without idiopathic pulmonary fibrosis.
(A) Surgery-related complications
LC with IPF (n = 96) LC without IPF (n = 192) P-value
Pneumonia 11 (11.5) 25 (13.0) 0.706
Pneumothorax 20 (20.8) 24 (12.0) 0.509
BPF 1 (1.0) 2 (1.0) 1.000
Prolonged MV 2 (2.1) 10 (5.2) 0.224
Arrythmia 1 (1.0) 2 (1.0) 1.000
Bleeding 2 (2.1) 3 (1.6) 0.751
ARDS� 2 (2.1) 2 (1.0) 0.255
AE–IPF 5 (5.2) –
ARDS or AE–IPF 7 (7.3) 2 (1.0) 0.012
(B) Adjuvant treatment-related complication (n = 110)
Postoperative hospital day 10.2 ± 10.0 9.8 ± 11.9 0.780
LC with IPF (n = 30) LC without IPF (n = 80) P-value
Cytopenia 2 (6.7) 17 (21.2) 0.091
GI trouble 8 (26.7) 28 (35.0) 0.409
Pneumonia 6 (20.0) 6 (7.5) 0.071
Pneumonitis 1 (3.4) 1 (1.2) 0.469
AE–IPF 2 (6.7) 0 (0.0) 0.126
Values are expressed as number (%).
�ARDS other than AE-IPF
AE-IPF, acute exacerbation of idiopathic pulmonary fibrosis; ARDS, acute respiratory distress syndrome; BPF, bronchopleural fistula; GI, gastrointestinal; LC, lung
cancer; MV, mechanical ventilation
https://doi.org/10.1371/journal.pone.0235126.t004
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Fig 2. Probability of recurrence-free survival and overall survival for patients with surgically resected non-small
cell lung cancer with or without IPF. (A) Recurrence-free survival was significantly lower in the LC with IPF group
than in the LC without IPF (P<0.001). (B) Overall survival was significantly lower in the LC with IPF group than in the
LC without IPF (P<0.001).
https://doi.org/10.1371/journal.pone.0235126.g002
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resection is associated with a lower incidence of surgery-related complications and better
short-term outcomes than is lobectomy, although the long-term outcomes are worse with
wedge resection, probably due to a higher recurrence rate. In the present study, however, mul-
tivariable analysis for recurrence-free survival showed that IPF and postoperative stage III
were independent risk factors for recurrence after adjustment for other variables, including
the surgical extent. In order to confirm that inferior recurrence-free survival and overall
survival in the LC with IPF group were not due to the difference in surgical extent between
groups, subgroup analysis was performed for patients who underwent lobectomy in the pro-
pensity score matched population. Subgroup analysis showed that recurrence-free survival,
overall survival and cancer-specific survival were significantly inferior in the LC with IPF
group than in the LC without IPF group (S1 and S2 Figs).
Unlike previous studies on patients with NSCLC and IPF, we assessed detailed surgery-
related variables, including whether or not mediastinal lymph node dissection was performed,
the number of dissected LNs and resection margin status. However, none were found to be sig-
nificant predictors of recurrence-free survival. Therefore, IPF itself appears to increase the risk
of lung carcinogenesis and recurrence after curative resection. This may be explained by the
aforementioned pathways for carcinogenesis in IPF, along with the possibility that tumors that
developed within fibrotic lesions could be obscured by honeycombing or reticular changes in
fibrotic lesions and consequently overlooked. Moreover, the probability of undiscovered posi-
tive LNs is higher for patients with IPF; this can be explained by the lower number of dissected
LNs in our IPF group, which could lead to stage migration and remnant malignancy [32].
Previous studies showed that morbidity and mortality rates after the surgical treatment of
NSCLC were significantly higher in patients with IPF than in those without IPF, and inferred
Table 5. Recurrence and overall survival in patients with surgically resected non-small cell lung cancer with or
without idiopathic pulmonary fibrosis.
LC with IPF (n = 96) LC without IPF (n = 192) P-value
Recurrence 43 (44.8) 49 (25.5) 0.002
Type of recurrence 0.062
Local recurrence 11 (25.6%) 4 (8.2%)
Regional recurrence 7 (16.3%) 13 (26.5%)
Distant metastasis 25 (58.1%) 32 (65.3)
5-year recurrence-free survival rate (%), 95% CI 49.2 (39.4–61.4) 69.1 (61.9–77.0) <0.001
Recurrence-free survival (months), 95% CI 48.8 (23.0–NA) NA
Death 61 (63.5%) 67 (34.9%) <0.001
Cause of death
Lung cancer progression 30 (31.2%) 36 (18.8%)
Surgery-related complication� 5 (5.2%) 9 (4.7%)
IPF progression or acute exacerbation 10 (10.4%) NA
Pneumonia 9 (9.4%) 8 (4.2%)
Other�� 7 (2.4%) 14 (7.3%)
5-year survival rate (%), 95% CI 45.9 (36.5–57.7) 64.8 (57.9–72.6) <0.001
Overall survival (months), 95% CI 49.5 (35.9–68.0) 172.0 (NA–NA)
Cancer specific survival (months), 95% CI 89.3 (68.0–NA) 172.0 (NA–NA) 0.008
Values are expressed as number (%).
IPF, idiopathic pulmonary fibrosis; LC, lung cancer
� The duration between surgery and the onset of complications was�4 weeks
�� 1 heart failure, 1 stomach perforation, 3 sepsis, 3 other cancer, 13 unknown
https://doi.org/10.1371/journal.pone.0235126.t005
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Table 6. Stratified Cox regression analyses for recurrence and mortality after surgical treatment of non-small cell lung cancer in patients with or without idiopathic
pulmonary fibrosis (propensity score-matched population).
(A) Stratified Cox regression analyses for recurrence
Univariable Multivariable
HR 95%CI p-value HR 95%CI p-value
IPF 2.86 1.72–4.76 <0.001 2.68 1.53–5.76 0.001
Sex 2.34 0.83–6.59 0.108
Age 0.97 0.92–1.02 0.236
Smoking (pack-years) 0.99 0.98–1.00 0.173
ECOG�2 5.16 0.52–50.41 0.158
FVC % pred 1.00 0.98–1.01 0.640
FEV1% pred 1.00 0.99–1.02 0.527
Postoperative Stage
I 1.00
II 2.00 0.91–4.39 0.084 2.39 0.78–7.30 0.339
III 5.19 1.98–13.64 <0.001 5.46 1.72–17.37 0.004
Surgery extent
Wedge resection 1.00
Segmentectomy 0.30 0.06–1.59 0.158 0.85 0.11–6.85 0.882
Lobectomy 0.26 0.07–0.93 0.038 1.36 0.23–8.07 0.738
Biolobectomy 0.22 0.04–1.17 0.076 1.64 0.17–16.05 0.670
Pneumonectomy 0.77 0.12–4.83 0.780 3.56 0.30–41.80 0.313
MLND 0.17 0.05–0.65 0.009 0.24 0.04–1.70 0.154
Dissected LN (n) 0.99 0.96–1.01 0.257
Resection margin 1.47 0.44–4.86 0.529
Adjuvant chemotherapy� 1.28 0.72–2.27 0.400 0.95 0.42–2.18 0.905
(B) Stratified Cox regression analyses for mortality
Univariable Multivariable
HR 95%CI p-value HR 95%CI p-value
IPF 2.38 1.56–3.64 <0.001 1.98 1.12–3.47 0.018
Sex 0.81 0.33–2.00 0.652
Age 0.97 0.93–1.02 0.227
Smoking (pack-years) 1.00 1.00–1.01 0.722
ECOG�2 5.16 1.03–25.86 0.046 1.73 0.90–3.33 0.101
FVC % pred 0.98 0.97–1.00 0.049 0.98 0.96–1.01 0.219
FEV1% pred 0.99 0.98–1.00 0.113
Postoperative Stage
I 1.00
II 1.49 0.81–2.73 0.196 1.83 0.79–4.23 0.158
III 3.56 1.67–7.60 <0.001 3.39 1.28–8.97 0.014
Surgery extent
Wedge resection 1.00
Segmentectomy 1.02 0.22–4.64 0.982 1.01 0.17–5.92 0.993
Lobectomy 0.27 0.09–0.80 0.018 0.41 0.10–1.61 0.200
Biolobectomy 0.55 0.16–1.90 0.345 0.86 0.18–4.14 0.848
Pneumonectomy 1.67 0.38–7.25 0.496 2.43 0.39–15.31 0.344
MLND 0.60 0.21–1.68 0.330
Dissected LN (n) 0.99 0.97–1.01 0.259
Resection margin 1.00 0.36–2.78 1.000
(Continued)
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that AE-IPF is the main cause of morbidity and mortality [12–14, 30]. The present study also
found a higher incidence of surgery-related AE-IPF or ARDS in the LC with IPF group. Multi-
variable analysis for overall survival reconfirmed that surgery-related AE-IPF or ARDS, along
with IPF itself and postoperative stage III, was an independent risk factor for overall survival.
Therefore, close monitoring of postoperative respiratory complications in patients with IPF
is important. DLCO, which showed a significant difference between the LC with IPF and LC
without IPF groups in the propensity score-matched population, was excluded from the Cox
regression model due to 39 patients with missing DLCO data in the LC without IPF group.
The DLCO test was mainly missed in patients without underlying lung fibrosis and respiratory
symptoms before surgery. Nevertheless, since DLCO has been reported as a risk factor for post-
operative respiratory complication, patients with a low DLCO should be carefully evaluated,
particularly for surgery-related AE-IPF or ARDS [33].
This study had several limitations. First, as the surgical extent was not included in propen-
sity score matching due to lack of data, the LC with IPF group received sublobar resection
more frequently compared to the LC without IPF group in the propensity matched population,
which can be a risk factor for recurrence. To cope with these limitations, stratified Cox regres-
sion analysis was conducted including the surgical extent, and it revealed that IPF and cancer
stage were independent risk factor for recurrence regardless of surgical extent. Second, more
detailed surgical and tumor variables that can affect recurrence, including the distance from
the tumor to the resection margin, visceral pleural invasion, angiolymphatic invasion, and the
degree of tumor differentiation, were not available for analysis. Lastly, this study had a retro-
spective nonrandomized design, which is associated with various biases and confounding
factors. However, we obtained the data from two tertiary care hospitals to minimize biases.
Further studies with a larger patient sample are required to validate our findings.
Conclusions
The present study revealed that the recurrence-free survival rate after curative surgical resec-
tion of stage I–III NSCLC was significantly lower for patients with IPF than for those without
IPF, and that IPF and postoperative stage III were predictors of both recurrence and mortality.
These findings suggest that close surveillance for recurrence after curative surgical resection
of NSCLC is mandatory if the patient has underlying IPF. We suggest that the conventional
regimen involving follow-up computed tomography every 6 months after surgery should be
replaced with a regimen involving follow-up visits at shorter intervals in patients with underly-
ing IPF, regardless of the surgical extent especially in higher cancer stage.
Supporting information
S1 Fig. Probability of cancer specific survival for patients with surgically resected non-
small cell lung cancer with or without IPF. (A) Cancer-specific survival was significantly
Table 6. (Continued)
AE+ARDS 16.00 2.00–127.90 0.009 14.02 1.55–126.89 0.019
Adjuvant chemotherapy� 0.94 0.56–1.58 0.830 0.92 0.45–1.88 0.810
AE or ARDS, acute exacerbation of idiopathic pulmonary fibrosis or acute respiratory distress syndrome; DLCO, diffusing capacity of the lungs for carbon monoxide;
ECOG, Eastern Cooperative Oncology Group; FVC, forced vital capacity; FEV1, Forced expiratory volume in one second; MLND, modified lymph node resection; LN,
lymph node; IPF, idiopathic pulmonary fibrosis
�Use of any chemotherapy including chemotherapy, Concurrent chemoradiotherapy, Sequential radiotherapy after chemotherapy
https://doi.org/10.1371/journal.pone.0235126.t006
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inferior in the LC with IPF group compared to the LC without IPF group in the whole propen-
sity score matched population (P = 0.008). (B) Cancer-specific survival was significantly
inferior in the LC with IPF group compared to the LC without IPF group in patients who
underwent lobectomy among the propensity score-matched population (P = 0.007).
(PPTX)
S2 Fig. Probability of recurrence-free survival and overall survival in patients who under-
went lobectomy among propensity score-matched population. (A) Recurrence-free
survival was significantly inferior in the LC with IPF group than in the LC without IPF group
(P = 0.003). (B) Overall survival was also significantly inferior in the LC with IPF group than
in the LC without IPF group (P<0.001).
(PPTX)
S1 Data. Relevant data.
(XLSX)
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